E. Taylor Stone

The paper develops mRNA-LNP vaccines encoding optimized prM/ENV proteins for all four DENV serotypes that induce protective immunity and reduce antibody-dependent enhancement.

This paper develops a Powassan virus-like-particle (POW-VLP) vaccine adjuvanted with INI-4001, showing it enhances immunogenicity, reduces viral burden, and provides full protection in mice.

This study shows that metabolic syndrome worsens SARS-CoV-2 disease and lowers vaccine effectiveness in mice.

This study shows that CD4+ and CD8+ T cells are necessary to prevent SARS-CoV-2 persistence in the nasal compartment but not in the lungs.